Third Harmonic Bio Ownership | Who Owns Third Harmonic Bio?
Third Harmonic Bio Ownership Summary
Third Harmonic Bio is owned by 107.67% institutional investors, 9.13% insiders. Atlas venture life science advisors is the largest institutional shareholder, holding 25.18% of THRD shares. T. Rowe Price Small-Cap Value is the top mutual fund, with 1.94% of its assets in Third Harmonic Bio shares.
THRD Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Third Harmonic Bio | 107.67% | 9.13% | -16.80% |
Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Atlas venture life science advisors | 10.40M | 25.18% | $107.04M |
Orbimed advisors | 5.78M | 13.99% | $59.47M |
General atlantic | 3.37M | 8.16% | $34.70M |
Ecor1 capital | 3.18M | 7.70% | $32.75M |
T. rowe price investment management | 2.93M | 7.09% | $30.14M |
Fmr | 2.54M | 6.14% | $26.10M |
Tcg crossover management | 2.51M | 6.06% | $25.78M |
Bvf inc/il | 2.37M | 5.74% | $24.42M |
Boxer capital | 2.00M | 4.93% | $26.00M |
Blackrock funding, inc. /de | 1.48M | 3.58% | $15.21M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Atlas venture life science advisors | 10.40M | 13.06% | $107.04M |
Tcg crossover management | 2.51M | 2.52% | $25.78M |
Takeda pharmaceutical | 36.84K | 1.43% | $379.03K |
Boxer capital | 2.00M | 1.37% | $26.00M |
Ecor1 capital | 3.18M | 1.24% | $32.75M |
General atlantic | 3.37M | 1.24% | $34.70M |
Orbimed advisors | 5.78M | 1.23% | $59.47M |
Bvf inc/il | 2.37M | 0.83% | $24.42M |
Acuta capital partners | 49.80K | 0.52% | $512.44K |
Nantahala capital management | 501.00K | 0.22% | $5.16M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Fmr | 2.54M | 0.00% | 2.23M |
Deerfield management company, l.p. (series c) | 1.02M | 0.20% | 1.02M |
Millennium management | 640.08K | 0.00% | 558.62K |
Nantahala capital management | 501.00K | 0.22% | 501.00K |
General atlantic | 3.37M | 1.24% | 413.56K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Bvf inc/il | 2.37M | 0.83% | -1.99M |
Commodore capital lp | 237.70K | 0.18% | -1.12M |
Atlas venture life science advisors | 10.40M | 13.06% | -505.57K |
Ra capital management | 960.62K | 0.13% | -320.21K |
Point72 asset management | - | - | -319.33K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Deerfield management company, l.p. (series c) | 1.02M | 0.20% | 1.02M | $10.49M |
Nantahala capital management | 501.00K | 0.22% | 501.00K | $5.16M |
Price t rowe associates inc /md/ | 361.89K | 0.00% | 361.89K | $3.73M |
Tang capital management | 150.00K | 0.10% | 150.00K | $1.54M |
Ikarian capital | 100.00K | 0.14% | 100.00K | $1.03M |
Sold Out
Holder | Change |
---|---|
Capital performance advisors llp | -25.00 |
Gamma investing | -97.00 |
Covestor | -251.00 |
Baldwin brothers llc/ma | -262.00 |
Federated hermes | -661.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 94 | 10.59% | 44,487,886 | 1.04% | 107 | 0.95% | 59 | 18.00% | 19 | 5.56% |
Sep 30, 2024 | 85 | 13.33% | 44,027,892 | 9.42% | 106 | 1.08% | 50 | 8.70% | 18 | 20.00% |
Jun 30, 2024 | 75 | 8.70% | 40,236,421 | 6.25% | 99 | 1.12% | 46 | 35.29% | 15 | -16.67% |
Mar 31, 2024 | 69 | 13.11% | 37,870,562 | -0.13% | 94 | 1.04% | 34 | -15.00% | 18 | 38.46% |
Dec 31, 2023 | 61 | 10.91% | 37,920,135 | 0.34% | 94 | 1.05% | 40 | 33.33% | 13 | 18.18% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
T. Rowe Price Small-Cap Value | 872.50K | 1.94% | -634.00 |
Fidelity Select Health Care | 680.00K | 1.52% | - |
Vanguard Total Stock Mkt Idx Inv | 636.12K | 1.42% | - |
Fidelity Small Cap Growth | 548.60K | 1.22% | - |
T. Rowe Price US Small-Cap Core Equity | 544.31K | 1.21% | -20.31K |
iShares Russell 2000 ETF | 524.63K | 1.16% | -4.57K |
Vanguard US Total Market Shares ETF | 517.12K | 1.15% | - |
T. Rowe Price U.S. SC Value Eq Tr-Z | 483.81K | 1.07% | 40.76K |
T. Rowe Price U.S. SC Value Eq Tr-D | 483.81K | 1.07% | 40.76K |
Fidelity Advisor Health Care I | 400.00K | 0.89% | - |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Nov 08, 2024 | Conner Edward R. | Chief Medical Officer | Sell | $31.75K |
Oct 29, 2024 | BVF PARTNERS L P/IL | See Explanation of Responses | Sell | $5.68M |
Oct 29, 2024 | BVF PARTNERS L P/IL | See Explanation of Responses | Sell | $7.70M |
Oct 29, 2024 | BVF PARTNERS L P/IL | See Explanation of Responses | Sell | $924.02K |
Oct 28, 2024 | Conner Edward R. | Chief Medical Officer | Sell | $40.09K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | - |
2024 Q4 | - | 5 |
2024 Q3 | - | 3 |
2024 Q2 | - | 7 |
2024 Q1 | - | - |
THRD Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools